Education
About Us
Working with TipRanks
Follow Us
Denali Therapeutics (DNLI)
NASDAQ:DNLI
DNLI Stock Chart & Stats
Day’s Range― - ―
52-Week Range$10.57 - $33.33
Previous CloseN/A
Volume399.31K
Average Volume (3M)2.21M
Market Cap
$2.18B
Enterprise Value$1.55B
Total Cash (Recent Filing)$898.95M
Total Debt (Recent Filing)$46.56M
Price to Earnings (P/E)―
Beta2.19
Next Earnings
Oct 30, 2025EPS Estimate
-0.75Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.72
Shares Outstanding146,212,280
10 Day Avg. Volume1,929,867
30 Day Avg. Volume2,211,141
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.71
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-507.78
Enterprise Value/Ebitda-3.02
Forecast
1Y Price Target
$32.20Price Target Upside99.13% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
Bulls Say, Bears Say
Bulls Say
Financial PositionThe company ended the quarter with ~$977M in cash which it expects to fund operations into 2028.
Regulatory ApprovalThe BLA for DNL310 in Hunter Syndrome/MPS II was accepted with Priority Review and a PDUFA date of January 5, 2026.
Unmet Medical NeedThere are currently no approved treatments for Sanfilippo syndrome Type A, indicating an unmet medical need that Denali's treatment could address.
Bears Say
Clinical Data49-week data from the ongoing open-label Phase I/II trial of DNL126 are consistent with previously announced data, including normalization of CSF HS levels.
Market CompetitionSwitching MPS II patients from the existing drug should be much faster than normal, especially in children, as the clinical program was based on switches.
Regulatory PathwayDenali must navigate the challenges which Elaprase faced with a more sophisticated launch strategy for tividenofusp alfa.
Denali Therapeutics News
DNLI FAQ
What was Denali Therapeutics’s price range in the past 12 months?
Denali Therapeutics lowest stock price was $10.57 and its highest was $33.33 in the past 12 months.
What is Denali Therapeutics’s market cap?
Denali Therapeutics’s market cap is $2.18B.
When is Denali Therapeutics’s upcoming earnings report date?
Denali Therapeutics’s upcoming earnings report date is Oct 30, 2025 which is in 20 days.
How were Denali Therapeutics’s earnings last quarter?
Denali Therapeutics released its earnings results on Aug 11, 2025. The company reported -$0.72 earnings per share for the quarter, missing the consensus estimate of -$0.71 by -$0.01.
Is Denali Therapeutics overvalued?
According to Wall Street analysts Denali Therapeutics’s price is currently Undervalued.
Does Denali Therapeutics pay dividends?
Denali Therapeutics does not currently pay dividends.
What is Denali Therapeutics’s EPS estimate?
Denali Therapeutics’s EPS estimate is -0.75.
How many shares outstanding does Denali Therapeutics have?
Denali Therapeutics has 146,212,280 shares outstanding.
What happened to Denali Therapeutics’s price movement after its last earnings report?
Denali Therapeutics reported an EPS of -$0.72 in its last earnings report, missing expectations of -$0.71. Following the earnings report the stock price went down -5.029%.
Which hedge fund is a major shareholder of Denali Therapeutics?
Currently, no hedge funds are holding shares in DNLI
Denali Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$32.20 (99.13% Upside)
$32.20 (99.13% Upside)
Blogger Sentiment
Bullish
DNLI Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 172.8K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $79.8K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 8.3%
Last 30 Days ▲ 14.4%
Last 30 Days ▲ 14.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-39.02%
12-Months-Change
Fundamentals
Return on Equity
-39.69%
Trailing 12-Months
Asset Growth
-22.38%
Trailing 12-Months
Company Description
Denali Therapeutics
Denali Therapeutics Inc. is a biopharmaceutical company focused on discovering and developing therapies for neurodegenerative diseases, such as Alzheimer's, Parkinson's, and ALS. The company operates in the biotechnology sector, leveraging its expertise in the biology of neurodegeneration to create a diverse pipeline of product candidates. Denali's core services include the development of small molecules, antibodies, and other therapeutic modalities aimed at addressing the underlying mechanisms of neurodegenerative conditions.
DNLI Stock 12 Month Forecast
Average Price Target
$32.20
▲(99.13% Upside)
Technical Analysis
Agios Pharma
―
Celcuity
―
IDEAYA Biosciences
―
Arcutis Biotherapeutics
―
Beam Therapeutics
―
Ownership Overview
7.23% Insiders
34.53% Mutual Funds
31.63% Other Institutional Investors
12.17% Public Companies and
Individual Investors